Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol

References

• RabeKFHurdSAnzuetoAGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med20071766532555
   PubMed Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management and Prevention of COPDGlobal Initiative for Chronic Obstructive Lung Disease (GOLD)2013 Available from: http://www.goldcopd.org/Accessed March 7, 2013
   Google Scholar
• MrozRMMinarowskiLChyczewskaEIndacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patientsAdv Exp Med Biol2013756232822836615
   PubMed Web of Science ®Google Scholar
• VogelmeierCKardosPHarariSGansSJStengleinSThirlwellJFormoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month studyRespir Med2008102111511152018804362
   PubMed Web of Science ®Google Scholar
• MillsEJThorlundKIoannidisJPCalculating additive treatment effects from multiple randomized trials provides useful estimates of combination therapiesJ Clin Epidemiol201265121282128822981250
   PubMed Web of Science ®Google Scholar
• McKeageKIndacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary diseaseDrugs201272454356322356291
   PubMed Web of Science ®Google Scholar
• DonohueJFJonesPWChanging patterns in long-acting bronchodilator trials in chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20116354521311692
   PubMed Web of Science ®Google Scholar
• AlbertPAgustiAEdwardsLBronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary diseaseThorax2012678701708
   PubMed Web of Science ®Google Scholar
• DecramerMCelliBKestenSLystigTMehraSTashkinDPUPLIFT investigaotrsEffect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trialLancet200937496961171117819716598
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationPulmonary-Allergy Drugs Advisory Committee Meeting: NDA 203108: Olodaterol (Proposed Trade Name Striverdi Respimat) for The Proposed Indication of Long-Term, Once-Daily Maintenance Bronchodilator Treatment of Airflow Obstruction in Patients with Chronic Obstructive Pulmonary Disease (Copd), Including Chronic Bronchitis and/or Emphysema2013 Available from: http://www.assets.fiercemarkets.com/public/lifesciences/pulmonary.pdfAccessed March 28, 2013
   Google Scholar
• Novartis Pharmaceuticals Canada IncOnbrez Breezhaler [product monograph]2011 [updated 2012]. Available from: http://www.novartis.ca/products/en/pharmaceuticals-o.shtmlAccessed March 27, 2013
   Google Scholar
• Novartis Pharmaceuticals CorporationArcapta Neohaler [prescribing information]2012 Available from: http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/arcapta.pdfAccessed March 27, 2013
   Google Scholar
• Novartis Europharm LimitedSummary of product characteristics for Onbrez Breezhaler2012 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001114/human_med_001219.jsp&mid=WC0b01ac058001d124Accessed March 7, 2013
   Google Scholar
• National Institute for Health and Care ExcellenceSpecification for Manufacturer/Sponsor Submission Of Evidence2009 Available from: http://www.nice.org.uk/aboutnice/howwework/devnicetech/SpecificationForManufacturerSponsorSubmissionOfEvidence.jspAccessed July 16, 2012
   Google Scholar
• FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
   PubMed Web of Science ®Google Scholar
• KochAPizzichiniEHamiltonALung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis20149697714
   PubMed Web of Science ®Google Scholar
• FeldmanGJBernsteinJAHamiltonANivensMCKorduckiLLaForceCThe 24-h FEV1 Time Profile of Olodaterol Once Daily via Respimat® and Formoterol Twice Daily via Aerolizer® in Patients with GOLD 2–4 COPD: Results from Two 6-week Crossover StudiesSpringer Plus In press2014
   Google Scholar
• LangePAumannJLHamiltonATetzlaffKTingNDeromEThe 24-hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary diseaseJ Pulm Respir Med In press2014
   Google Scholar
• Centre for Reviews and DisseminationCRD’s Guidance for Undertaking Reviews in Health Care University of York: Centre for Reviews and Dissemination2009 Available from: http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdfAccessed August 30, 2012
   Google Scholar
• JonesBRogerJLanePWStatistical approaches for conducting network meta-analysis in drug developmentPharm Stat201110652353122213533
   PubMed Web of Science ®Google Scholar
• WhiteheadAMeta-Analysis of Controlled Clinical TrialsChichester, West Sussex, EnglandJohn Wiley and Sons Ltd2002
   Google Scholar
• BucherHCGuyattGHGriffithLEWalterSDThe results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJ Clin Epidemiol19975066836919250266
   PubMed Web of Science ®Google Scholar
• SongFAltmanDGGlennyAMDeeksJJValidity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analysesBMJ2003326472
   PubMed Web of Science ®Google Scholar
• MahlerDAD’UrzoABatemanEDConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomized, double-blind comparisonThorax201267978178822544891
   PubMed Web of Science ®Google Scholar
• KinoshitaMLeeS-HHangL-WEfficacy and safety of indacaterol 150 and 300g in Asian COPD patients: a 12-week, placebo controlled studyAmerican Thoracic Society International ConferenceMay 13–18, 2011Denver, Colorado Abstract no A1593
   Google Scholar
• BeierJChanezPMartinotJBSafety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomized, placebo controlled clinical trialPulm Pharmacol Ther200720674074917088091
   PubMed Web of Science ®Google Scholar
• Study B2354. Reported in Center for Drug Evaluation and Research summary review document for indacaterol2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000TOC.cfmAccessed January 4, 2012
   Google Scholar
• Study B2355. Reported in Center for Drug Evaluation and Research summary review document for indacaterol2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000TOC.cfmAccessed January 4, 2012
   Google Scholar
• DonohueJFFogartyCLotvallJOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
   PubMed Web of Science ®Google Scholar
• FeldmanGSilerTPrasadNINLIGHT 1 study groupEfficacy and safety of indacaterol 150 microg. once-daily in COPD: a double-blind, randomized, 12-week studyBMC Pulm Med2010101120211002
   PubMed Web of Science ®Google Scholar
• KornmannODahlRCentanniSOnce-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243
   PubMed Web of Science ®Google Scholar
• KornSKerwinEAtisSAmosCOwenRLassenCIndacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week studyRespir Med2011105571972621367594
   PubMed Web of Science ®Google Scholar
• BuhlRDunnLJDisdierCINTENSITY study investigatorsBlinded 12-week comparison of once-daily indacaterol and tiotropium in COPDEur Respir J201138479780321622587
   PubMed Web of Science ®Google Scholar
• DahlRChungKFBuhlREfficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax2010656473479
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGThe PRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: The PRISMA statementPLoS Med200966e100009719621072
   PubMed Web of Science ®Google Scholar
• CopeSCapkun-NiggliGGaleREfficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparisonValue Health2012153524533
   Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management and Prevention of COPD, Revised 2011 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdfAccessed March 28, 2013
   Google Scholar
• RenardDLoobyMKramerBLawrenceDMorrisDStanskiDRCharacterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model based approachesRespir Res2011125421518459
   PubMed Web of Science ®Google Scholar
• BleeckerERSilerTOwenRKramerBBronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled dataInt J Chron Obstruct Pulmon Dis2011643143822003288
   PubMed Web of Science ®Google Scholar
• CopeSCapkun-NiggliGGaleRJardimJJansenJPComparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysisInt J Chron Obstruct Pulmon Dis2011632934421697997
   PubMed Web of Science ®Google Scholar
• CopeSZhangJWilliamsJJansenJPEfficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysisBMC Pulm Med2012122922732017
   PubMed Web of Science ®Google Scholar